Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DIOSynVax logo — Innovation in Vaccine Antigen Design

DIOSynVax

Innovation in Vaccine Antigen Design

Founded 2017 United Kingdom Cambridge, United Kingdom 22 employees Grant Total: $45.40M Biotechnology, Information Technology

General Information

Company Name DIOSynVax
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom +1
Employees 22
Industries Biotechnology, Information Technology
Funding Stage Grant
Social

Get notified when DIOSynVax moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About DIOSynVax

DIOSynVax is a UK-based biotech startup focused on transforming the way the world defends itself against infectious diseases and emerging pathogens. The company's proprietary technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), stands at the core of their mission. This innovative system aims to expedite vaccine development while significantly enhancing protection against emerging and re-emerging pathogens. Founded in 2017, DIOSynVax operates at the intersection of Biotechnology and Information Technology. The startup recently secured a substantial $42.00M grant investment from the Coalition for Epidemic Preparedness Innovations in March 08, 2022. This funding injection is expected to fuel the company's research and development efforts, potentially propelling their groundbreaking technology into the forefront of vaccine innovation. Overall, DIOSynVax's commitment to leveraging advanced technology to address global health challenges positions them as a promising player in the biotech landscape, especially as the world grapples with the need for swift and effective responses to emerging infectious threats. With noteworthy financial backing and a compelling vision, DIOSynVax holds the potential to significantly impact the future of vaccine development and global health security.

Taxonomy: biotech startup, vaccine development, infectious disease, pathogen protection, vaccine technology, immune optimization, digital antigen design, emerging pathogens, immunization innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
08 Mar 2022
Grant •••••• 1
Investor
26 Aug 2020
Seed Round •••••• 1
Investor
21 Jan 2020

DIOSynVax Alternatives & Competitors

DIOSynVax vs
GPN Vaccines
GPN Vaccines Australia

Developing innovative vaccines against the world's most important bacterial pathogens.

Series B
24 employees
Biotechnology
DIOSynVax vs
Biological Mimetics, Inc.
Biological Mimetics, Inc. United States

BMI is a leading edge, privately-held biomedical company focusing on vaccine and diagnostic developm...

9 employees
DIOSynVax vs
Helmholtz Centre for Infection Research
Helmholtz Centre for Infection Research Germany

Our research leads to new strategies in the fight against infectious diseases.

Grant
458 employees
Messaging

FAQ About DIOSynVax

Innovation in Vaccine Antigen Design
DIOSynVax was founded in 2017.
DIOSynVax is headquartered in Cambridge, United Kingdom.
DIOSynVax operates in the following industries: Biotechnology, Information Technology.
DIOSynVax has approximately 22 employees.
DIOSynVax has completed 3 funding rounds, raising a total of $45.40M. The latest funding stage is Grant.
Top alternatives and competitors to DIOSynVax include GPN Vaccines, Biological Mimetics, Inc., Helmholtz Centre for Infection Research, Vaxart, Inc., MEDIGEN, INC.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DIOSynVax and GPN Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors DIOSynVax and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes